These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 3064713)

  • 1. Immunohistochemical analysis of the ras oncogene protein product in human thyroid neoplasms.
    Papadimitriou K; Yiagnisis M; Tolis G; Spandidos DA
    Anticancer Res; 1988; 8(6):1223-7. PubMed ID: 3064713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Expression of ras oncogene product P21 in thyroid tumors: an immunohistochemical study].
    Gui K
    Zhonghua Yi Xue Za Zhi; 1990 Mar; 70(3):140-2, 12. PubMed ID: 2163739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential (Ha-, K- and N-) ras p21 expression in benign and malignant human thyroid tumors: an immunohistochemical study.
    Mizukami Y; Nonomura A; Michigishi T; Noguchi M; Nakamura S; Hashimoto T
    Anticancer Res; 1995; 15(3):755-9. PubMed ID: 7645954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of ras oncogene p21 antigen in normal and proliferative thyroid tissues.
    Johnson TL; Lloyd RV; Thor A
    Am J Pathol; 1987 Apr; 127(1):60-5. PubMed ID: 3105323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.
    Shi YF; Zou MJ; Schmidt H; Juhasz F; Stensky V; Robb D; Farid NR
    Cancer Res; 1991 May; 51(10):2690-3. PubMed ID: 2021946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of ras mutation in the progression of thyroid carcinoma of follicular epithelial origin.
    Motoi N; Sakamoto A; Yamochi T; Horiuchi H; Motoi T; Machinami R
    Pathol Res Pract; 2000; 196(1):1-7. PubMed ID: 10674266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thyroid targeting of the N-ras(Gln61Lys) oncogene in transgenic mice results in follicular tumors that progress to poorly differentiated carcinomas.
    Vitagliano D; Portella G; Troncone G; Francione A; Rossi C; Bruno A; Giorgini A; Coluzzi S; Nappi TC; Rothstein JL; Pasquinelli R; Chiappetta G; Terracciano D; Macchia V; Melillo RM; Fusco A; Santoro M
    Oncogene; 2006 Aug; 25(39):5467-74. PubMed ID: 16785999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas.
    Soda G; Antonaci A; Bosco D; Nardoni S; Melis M
    J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical study of the ras oncogene expression in human breast lesions.
    Agnantis NJ; Petraki C; Markoulatos P; Spandidos DA
    Anticancer Res; 1986; 6(5):1157-60. PubMed ID: 3541779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue.
    Cvejic D; Savin S; Paunovic I; Tatic S; Havelka M; Sinadinovic J
    Anticancer Res; 1998; 18(4A):2637-41. PubMed ID: 9703921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of activated ras oncogenes in human thyroid carcinomas.
    Suárez HG; Du Villard JA; Caillou B; Schlumberger M; Tubiana M; Parmentier C; Monier R
    Oncogene; 1988 Apr; 2(4):403-6. PubMed ID: 3283656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of protooncogene bcl-2 in thyroid tumors].
    Zhu J; Chen Y; Xue H
    Zhonghua Yi Xue Za Zhi; 1996 Nov; 76(11):829-31. PubMed ID: 9275533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal preservation of p21 ras immunoreactivity and morphology in paraffin-embedded tissue.
    Going JJ; Williams AR; Wyllie AH; Anderson TJ; Piris J
    J Pathol; 1988 Jul; 155(3):185-90. PubMed ID: 3045276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhanced expression of c-Ha-ras p21 in human stomach adenocarcinomas defined by immunoassays using monoclonal antibodies and in situ hybridization.
    Ohuchi N; Hand PH; Merlo G; Fujita J; Mariani-Costantini R; Thor A; Nose M; Callahan R; Schlom J
    Cancer Res; 1987 Mar; 47(5):1413-20. PubMed ID: 2434216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The natural protein kinase C alpha mutant is present in human thyroid neoplasms.
    Prévostel C; Alvaro V; de Boisvilliers F; Martin A; Jaffiol C; Joubert D
    Oncogene; 1995 Aug; 11(4):669-74. PubMed ID: 7651730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD117 expression in normal, neoplastic, inflammatory, and reactive lesions of the thyroid.
    Aydin O; Yildiz L; Kefeli M; Kandemir B
    Pathol Res Pract; 2008; 204(6):359-65. PubMed ID: 18337018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications.
    Chevillard S; Ugolin N; Vielh P; Ory K; Levalois C; Elliott D; Clayman GL; El-Naggar AK
    Clin Cancer Res; 2004 Oct; 10(19):6586-97. PubMed ID: 15475448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
    Tanaka T; Slamon DJ; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
    Cancer Res; 1988 Feb; 48(4):1030-4. PubMed ID: 3276397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunohistochemical studies of ras oncogene product p21 in human ovarian tumors].
    Yaginuma Y; Yamashita K
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1409-16. PubMed ID: 2685141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphotyrosine, p62 c-myc and p21 c-Ha-ras proteins in colonic epithelium of normal and dimethylhydrazine-treated rats: an immunohistochemical analysis.
    Schwartz B; Benharroch D; Prinsloo I; Cagnano E; Lamprecht SA
    Anticancer Res; 1995; 15(1):211-8. PubMed ID: 7537485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.